<DOC>
	<DOCNO>NCT02110160</DOCNO>
	<brief_summary>The purpose study assess utility FDG PET/CT evaluate response bone dominant breast cancer therapy . Eligible patient bone dominant ER+ breast cancer undergo baseline FDG PET/CT evaluation disease , start therapy undergo FDG PET/CT scan 4 week 12 week . PET/CT result compare clinical measure response , time progression overall survival .</brief_summary>
	<brief_title>18F-Fluorodeoxyglucose ( FDG ) Positron Emission Tomography ( PET/CT ) For The Evaluation Of Response To Therapy In Bone-Dominant Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<mesh_term>Deoxyglucose</mesh_term>
	<criteria>Adult patient , least 18 year age , history pathologically confirm ER+ breast cancer Biopsy proven clinically obvious document bone metastasis breast cancer ( majority disease burden bone ) Patients plan start new endocrine target therapy ( line therapy acceptable endocrine therapy allow ) Willing able comply schedule visit serial imaging procedure Agrees allow access clinical record regard response treatment long term follow 6 . Be inform investigational nature study provide write informed consent accordance institutional federal guideline . Exclusion Criteria Women pregnant breast feeding Uncontrolled diabetes mellitus ( fast glucose great 200 mg/dL ) Inability tolerate imaging procedure ( e.g . claustrophobia , severe pain ) Weight exceed capacity image table Previous treatment radiation surgery significant percentage bony metastatic site 6 . Treatment marrow stimulate agent ( e.g . granulocyte colony stimulate factor ( GCSF ) ) within 3 week baseline scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>